Misplaced Pages

This is the current revision of this page, as edited by Citation bot (talk | contribs) at 01:12, 30 May 2023 (Add: s2cid. | Use this bot. Report bugs. | Suggested by Spinixster | Category:Blood and blood forming organ drug stubs | #UCB_Category 48/94). The present address (URL) is a permanent link to this version.

Parnaparin sodium

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	B01AB07 (WHO)
Identifiers
CAS Number	9041-08-1
DrugBank	DB09260
ChemSpider	none
UNII	U6K360XMIU
KEGG	D04977
(verify)

Parnaparin is an antithrombotic and belongs to the group of low molecular weight heparins. In the prevention and therapy of thromboembolic pathologies, the advent of this class of drugs represented a medical development, since they retain the same effectiveness of unfractionated heparin but with simpler dosing regimens and decreased side effects. In addition to being effective in treating proven deep vein thrombosis and thrombosis-associated phlebopathies, Parnaparin has demonstrated its thromboprophylactic efficacy in both high- and moderate-risk surgical patients.

External links

• parnaparin at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
• Maugeri N, Di Fabio G, Barbanti M, de Gaetano G, Donati MB, Cerletti C (2007). "Parnaparin, a low-molecular-weight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood". Thromb. Haemost. 97 (6): 965–73. doi:10.1160/th06-12-0680. PMID 17549299. S2CID 24068001.

This drug article relating to the blood and blood forming organs is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Heparins
• Blood and blood forming organ drug stubs